Xencor, Inc. (NASDAQ:XNCR) Given Average Rating of “Moderate Buy” by Analysts

Xencor, Inc. (NASDAQ:XNCR) has earned an average rating of “Moderate Buy” from the nine ratings firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $36.00.

A number of research analysts recently weighed in on XNCR shares. BMO Capital Markets cut their target price on shares of Xencor from $38.00 to $34.00 and set an “outperform” rating for the company in a report on Wednesday, February 28th. Mizuho decreased their target price on shares of Xencor from $59.00 to $50.00 and set a “buy” rating on the stock in a research report on Monday, January 22nd. Wedbush dropped their price target on Xencor from $36.00 to $34.00 and set an “outperform” rating for the company in a research report on Wednesday, February 28th. BTIG Research decreased their price objective on Xencor from $56.00 to $38.00 and set a “buy” rating on the stock in a research report on Tuesday, April 16th. Finally, Piper Sandler reaffirmed a “neutral” rating and issued a $24.00 price objective (down from $37.00) on shares of Xencor in a research note on Wednesday, February 28th.

Xencor Stock Up 2.0 %

Shares of XNCR stock opened at $24.11 on Friday. The company’s fifty day simple moving average is $21.88 and its two-hundred day simple moving average is $20.47. Xencor has a 52 week low of $16.49 and a 52 week high of $28.96. The stock has a market cap of $1.49 billion, a P/E ratio of -11.48 and a beta of 0.77. The company has a quick ratio of 7.36, a current ratio of 7.36 and a debt-to-equity ratio of 0.02.

Xencor (NASDAQ:XNCR) last issued its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.36 by ($0.67). The firm had revenue of $44.70 million during the quarter, compared to the consensus estimate of $77.63 million. Xencor had a negative return on equity of 18.67% and a negative net margin of 74.90%. The company’s revenue for the quarter was up 106.9% compared to the same quarter last year. During the same period last year, the firm posted ($0.20) earnings per share. Analysts predict that Xencor will post -3.25 EPS for the current fiscal year.

Insider Buying and Selling at Xencor

In other news, CEO Bassil I. Dahiyat sold 12,528 shares of Xencor stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $23.43, for a total transaction of $293,531.04. Following the completion of the sale, the chief executive officer now directly owns 300,097 shares in the company, valued at $7,031,272.71. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, VP John R. Desjarlais sold 54,108 shares of Xencor stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $19.38, for a total transaction of $1,048,613.04. Following the completion of the sale, the vice president now owns 161,675 shares of the company’s stock, valued at $3,133,261.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Bassil I. Dahiyat sold 12,528 shares of the stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $23.43, for a total value of $293,531.04. Following the completion of the transaction, the chief executive officer now directly owns 300,097 shares in the company, valued at approximately $7,031,272.71. The disclosure for this sale can be found here. Insiders have sold 101,351 shares of company stock valued at $2,152,417 in the last quarter. 4.97% of the stock is owned by insiders.

Institutional Investors Weigh In On Xencor

A number of institutional investors and hedge funds have recently bought and sold shares of XNCR. abrdn plc purchased a new position in shares of Xencor during the fourth quarter valued at $3,726,000. State of New Jersey Common Pension Fund D raised its holdings in shares of Xencor by 24.8% in the 3rd quarter. State of New Jersey Common Pension Fund D now owns 110,353 shares of the biopharmaceutical company’s stock valued at $2,224,000 after purchasing an additional 21,946 shares in the last quarter. Hudson Bay Capital Management LP raised its holdings in shares of Xencor by 144.7% in the 3rd quarter. Hudson Bay Capital Management LP now owns 232,500 shares of the biopharmaceutical company’s stock valued at $4,685,000 after purchasing an additional 137,500 shares in the last quarter. Deutsche Bank AG lifted its position in shares of Xencor by 13.0% in the 3rd quarter. Deutsche Bank AG now owns 33,098 shares of the biopharmaceutical company’s stock worth $667,000 after purchasing an additional 3,805 shares during the period. Finally, Diversified Trust Co bought a new position in shares of Xencor during the fourth quarter valued at approximately $265,000.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.